Locoregional IL-2 low dose applications for gastrointestinal tumors

doi:10.3748/wjg.v11.i35.5525

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 35

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2239)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

227

HTML

1888

Tables (1-2)

124

Sum=2239

Sep 21, 2005 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Sep 21, 2005; 11(35): 5525-5529
Published online Sep 21, 2005. doi: 10.3748/wjg.v11.i35.5525

Locoregional IL-2 low dose applications for gastrointestinal tumors

Zachary Krastev, V Koltchakov, R Tomova, S Deredjian, A Alexiev, D Popov, B Tomov, Jan-Willem Koten, John Jacobs, Willem Den Otter

Zachary Krastev, V Koltchakov, R Tomova, S Deredjian, A Alexiev, D Popov, B Tomov, Clinic of Gastroenterology, Faculty of Medicine, University Hospital, Blvd. Iv. Geshov 15, Sofia 1431, Bulgaria

Jan-Willem Koten, John Jacobs, Willem Den Otter, Department of Pathobiology, PO Box 80.178, 3508 TD Utrecht, The Netherlands

Author contributions: All authors contributed equally to the work.

Correspondence to: Professor Zachary Krastev, Clinic of Gastroenterology, University Hospital “St.I.Rilski”, #15 Blvd. “Iv.Geshov”, Sofia 1431, Bulgaria. zahkrastev@yahoo.com

Telephone: +359-2-58-12-827 Fax: +359-2-851-06-15

Received: January 7, 2005
Revised: April 15, 2005
Accepted: April 18, 2005
Published online: September 21, 2005

Abstract

AIM: To explore the feasibility of local interleukin 2 (IL-2) in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application.

METHODS: Sixteen patients with stages III and IV of gastrointestinal malignancies (primary or metastatic) who were admitted to our Department of Gastroenterology were treated with locoregionally applied IL-2 in low doses.

RESULTS: No major problems applying locoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. Adverse effects were minimal. The therapeutic scheme was well tolerated, even in patients in a poor condition.

CONCLUSION: This study demonstrates the feasibility of low dose locoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.

Keywords: Interleukin-2, Local IL-2 therapy, Gastrointestinal cancer